Orforglipron facilitates therapeutic metabolic regulation through a highly targeted small-molecule interaction:

• Biased Agonism at GLP-1R: As a synthetic small molecule, Orforglipron binds to a specific orthosteric pocket of the GLP-1 receptor. This interaction facilitates sustained cAMP production, promoting insulinotropic effects with high specificity.
•  
• Superior Pharmacokinetics: The non-peptide structure confers total resistance to proteolytic enzymes like DPP-4. Its intrinsic lipophilicity ensures reliable gastrointestinal absorption, achieving a long half-life suitable for once-daily oral administration.
•  
• Metabolic Impact: Beyond glycemic control, it activates satiety centers in the hypothalamus and delays gastric emptying, resulting in clinically significant weight reduction and improvement in cardiovascular-metabolic biomarkers.

• Oral Solid Dosage Development: The primary API for manufacturing 12mg to 45mg oral tablets indicated for Type 2 Diabetes and chronic weight management.
•  
• Metabolic Syndrome R&D: Utilized in preclinical and clinical studies exploring its impact on NAFLD/MASH and metabolic-associated cardiovascular risks.
•  
• Next-Generation Therapeutic Modeling: Serving as the gold-standard benchmark for researchers developing novel non-peptide GLP-1 analogues.

Oral Semaglutide (Rybelsus) is a peptide that requires SNAC for absorption and strict fasting protocols. Orforglipron is a non-peptide small molecule with high intrinsic permeability. It does not require absorption enhancers and can potentially be taken without the strict food/water restrictions required by peptide-based oral insulins.

What is the validated purity and impurity control for Orforglipron API?

At Xi'an Tihealth, we utilize RP-HPLC to ensure a purity of ≥99.0%. We strictly control process-related impurities and residual solvents (ICH Q3C). Every batch is supplied with a comprehensive Certificate of Analysis (COA) and LC-MS data to verify molecular identity and structural integrity.

Can Xi'an Tihealth provide technical dossiers for regulatory filings?

Yes. We provide a CTD-ready technical package for Orforglipron, including Method of Analysis (MOA), short-term and long-term stability data, and impurity profiling. Our team is committed to supporting our global partners through regulatory drug registration and GMP audits.

What are the cold-chain logistics protocols for international shipping?

We recognize the sensitivity of high-purity small molecules to temperature fluctuations. We utilize validated isothermal packaging with temperature loggers for international air freight, ensuring the API remains strictly at -20°C from our facility in Xi'an to your laboratory or manufacturing plant.

Does the manufacturing process comply with Non-Animal Origin (NAO) standards?

Absolutely. Orforglipron is 100% synthetically derived via chemical synthesis. We provide a formal TSE/BSE-free statement confirming that no animal-derived raw materials, enzymes, or catalysts are used in the production or purification processes, ensuring total safety for pharmaceutical use.